Can NK cells be a therapeutic target in human diseases?
- 6 November 2008
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 38 (11) , 2964-2968
- https://doi.org/10.1002/eji.200838764
Abstract
Our current knowledge of NK‐cell recognition and effector function suggests that it will be possible to design various new NK‐cell‐based immunotherapies against human cancer. The application of NK cells is already showing promise using HLA‐mismatched haematopoietic stem cell transplantation for treatment of haematological malignancies. A better understanding of NK‐cell heterogeneity and function will only broaden the applications for human cancer. Here we review the key developments that will propel this field.Keywords
This publication has 51 references indexed in Scilit:
- Expanded donor natural killer cell and IL‐2, IL‐15 treatment efficacy in allogeneic hematopoietic stem cell transplantationEuropean Journal of Haematology, 2008
- Correlation between NK function and response to trastuzumab in metastatic breast cancer patientsJournal of Translational Medicine, 2008
- NKG2D-Deficient Mice Are Defective in Tumor Surveillance in Models of Spontaneous MalignancyPublished by Elsevier ,2008
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007
- Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCTBlood, 2007
- Development of TLR9 agonists for cancer therapyJournal of Clinical Investigation, 2007
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomasNature, 2007
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- The DNA damage pathway regulates innate immune system ligands of the NKG2D receptorNature, 2005